Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
147,179,178
-
Total 13F shares
-
58,142,948
-
Share change
-
+49,117,533
-
Total reported value
-
$909,284,000
-
Price per share
-
$15.64
-
Number of holders
-
44
-
Value change
-
+$768,126,565
-
Number of buys
-
41
Institutional Holders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) as of Q4 2017
As of 31 Dec 2017,
Denali Therapeutics Inc. - COMMON STOCK (DNLI) was held by
44 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
58,142,948 shares.
The largest 10 holders included
Crestline Management, LP, FMR LLC, Flagship Pioneering Inc., BAILLIE GIFFORD & CO, Temasek Holdings (Private) Ltd, FIL Ltd, Vanguard Group Inc, NORGES BANK, Alphabet Inc., and Mitsubishi UFJ Trust & Banking Corp.
This page lists
44
institutional shareholders reporting positions in this security
for the Q4 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.